Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ML-007 by MapLight therapeutics for Alzheimer's Disease: Likelihood of Approval
ML-007 is under clinical development by MapLight therapeutics and currently in Phase I for Alzheimer's Disease. According to GlobalData, Phase...